These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 23454761)

  • 1. Rapalogs and mTOR inhibitors as anti-aging therapeutics.
    Lamming DW; Ye L; Sabatini DM; Baur JA
    J Clin Invest; 2013 Mar; 123(3):980-9. PubMed ID: 23454761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From rapalogs to anti-aging formula.
    Blagosklonny MV
    Oncotarget; 2017 May; 8(22):35492-35507. PubMed ID: 28548953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases.
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2011 Aug; 14(4):437-41. PubMed ID: 21851176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.
    Zhang YJ; Duan Y; Zheng XF
    Drug Discov Today; 2011 Apr; 16(7-8):325-31. PubMed ID: 21333749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting effects of chronic, systemic treatment with mTOR inhibitors rapamycin and metformin on adult neural progenitors in mice.
    Kusne Y; Goldberg EL; Parker SS; Hapak SM; Maskaykina IY; Chew WM; Limesand KH; Brooks HL; Price TJ; Sanai N; Nikolich-Zugich J; Ghosh S
    Age (Dordr); 2014 Feb; 36(1):199-212. PubMed ID: 23949159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updates of mTOR inhibitors.
    Zhou H; Luo Y; Huang S
    Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.
    Arriola Apelo SI; Lamming DW
    J Gerontol A Biol Sci Med Sci; 2016 Jul; 71(7):841-9. PubMed ID: 27208895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
    Marshall G; Howard Z; Dry J; Fenton S; Heathcote D; Gray N; Keen H; Logie A; Holt S; Smith P; Guichard SM
    Biochem Soc Trans; 2011 Apr; 39(2):456-9. PubMed ID: 21428919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
    Shi WY; Xiao D; Wang L; Dong LH; Yan ZX; Shen ZX; Chen SJ; Chen Y; Zhao WL
    Cell Death Dis; 2012 Mar; 3(3):e275. PubMed ID: 22378068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of mTOR inhibitor resistance in cancer therapy.
    Carew JS; Kelly KR; Nawrocki ST
    Target Oncol; 2011 Mar; 6(1):17-27. PubMed ID: 21547705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging and TOR: interwoven in the fabric of life.
    Sharp ZD
    Cell Mol Life Sci; 2011 Feb; 68(4):587-97. PubMed ID: 20960025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward rapamycin analog (rapalog)-based precision cancer therapy.
    Meng LH; Zheng XF
    Acta Pharmacol Sin; 2015 Oct; 36(10):1163-9. PubMed ID: 26299952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mTOR signaling pathway in ovarian cancer.
    Mabuchi S; Hisamatsu T; Kimura T
    Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

  • 15. Koschei the immortal and anti-aging drugs.
    Blagosklonny MV
    Cell Death Dis; 2014 Dec; 5(12):e1552. PubMed ID: 25476900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of mTOR in aging and cancer.
    Zhavoronkov A
    Oncotarget; 2015 Dec; 6(42):45010-1. PubMed ID: 26942715
    [No Abstract]   [Full Text] [Related]  

  • 17. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.
    Martinet W; De Loof H; De Meyer GRY
    Atherosclerosis; 2014 Apr; 233(2):601-607. PubMed ID: 24534455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin: one drug, many effects.
    Li J; Kim SG; Blenis J
    Cell Metab; 2014 Mar; 19(3):373-9. PubMed ID: 24508508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian target of rapamycin as a target in hematological malignancies.
    Kelly KR; Rowe JH; Padmanabhan S; Nawrocki ST; Carew JS
    Target Oncol; 2011 Mar; 6(1):53-61. PubMed ID: 21499765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.